

29 October 2026

Australian Securities Exchange
39 Martin Place
Sydney NSW 2000

Trading Update – FY27 year to date

Continued sales momentum delivering record contracted revenue

Melbourne, Victoria | [Alcidion Group Limited](#) (ASX:ALC) (**‘Alcidion’** or the **‘Company’**) today releases a trading update for the FY27 year to date. With Alcidion no longer required to lodge quarterly Appendix 4C cash flow reports, the Company is committed to keeping the market informed through regular trading updates.

Highlights:

- Expanded contract with Northern Care Alliance NHS Foundation Trust (**NCA**), moving from the existing ExtraMed Flow products to Miya and adding sites across the Trust.
 - Total Contract Value (TCV) of \$7.5M over 3 years with options to extend up to 5 years and \$4.5M expected to be recognised in FY27.
- Expanded Health NZ – MidCentral contract in New Zealand to include Whanganui Hospital.
- As of 30 September 2026, FY27 contracted (sold & renewal) revenue of \$50.0M, up 38% on the prior corresponding period (pcp).
- Announced Miya Patient Administration, extending the Miya platform with a modern, AI-enabled patient administration system (PAS).
- Integration of Kyra flow products business progressing well, with all transitional services now brought in-house and cost synergies being delivered through FY27.
- Announced an on-market share buy-back and share consolidation – both forming part of Alcidion’s broader capital allocation framework and strategies to drive long-term shareholder value.
- Reconfirmed FY27 guidance for revenue and Underlying EBITDA to exceed FY26.

Alcidion Managing Director and CEO Kate Quirke said: “FY27 has started strongly, providing further evidence of our land-and-expand go-to-market strategy. The NCA expanded contract represents an exciting opportunity for us, serving not only to increase our Annual Recurring Revenue (ARR) but also continuing to validate the rationale for our acquisition of ExtraMed in 2021. The expanded number of hospitals at NCA gives us a significant footprint in one of the larger NHS trusts and we see further opportunity for Miya to add value over time.”

“As Alcidion’s financial profile has strengthened, we have greater flexibility and confidence to deploy capital across opportunities that build long-term shareholder value. The launch of Miya Patient Administration shows our focus on the future of healthcare and our willingness to invest strategically in the areas we believe will deliver the strongest returns and address the most urgent needs of our customers. We know patient administration is an area where AI can add considerable value in automating tasks and providing significant efficiencies to the healthcare system. The investment we made in acquiring the PCS patient administration system via the Silverlink transaction gives us the foundation of intellectual property onto which we can deploy modern coding capabilities to rapidly produce a state-of-the-art patient administration function built for today’s healthcare system.

“In addition, and as part of our capital deployment program, the buy-back we recently announced gives us the flexibility to invest back into our company where we see compelling value.”

“Underpinned by a record Q1 contracted revenue position, we remain optimistic about the growth opportunities ahead, both in existing and emerging markets, with demand for digital solutions that accelerate and streamline patient movement through the hospital continuing to grow.”

Operational Update

New / Expanded contracts

- **Northern Care Alliance (UK)** – TCV of \$7.5M over 3 years with options to extend up to 5 years. Contract expansion will see Miya deployed at Salford Royal Hospital, replacing the Trust’s existing ExtraMed patient flow solution, and to additional sites within NCA. With a rapid implementation planned, the contract is expected to deliver \$4.5M of revenue in FY27, reflecting the speed with which Alcidion delivers value to its customers.
- **Health NZ MidCentral** – Contract expanded to include an additional site, Whanganui Hospital. MidCentral has used Miya since 2018 and was our first Miya customer in New Zealand. Extending Miya to additional hospitals will give the central region visibility of capacity across multiple hospitals.

New markets

- Our Canadian pipeline continues to build, and we are investing in a dedicated, full-time business development manager in the region to pursue the opportunities identified.
- We are progressing discussions with prospective resellers in the Middle East to provide on-the-ground sales and implementation capability for Miya.

Kyra products integration

- Integration of the Kyra flow products business (acquired on 29 June 2026) is progressing well, with cost synergies being delivered over the course of FY27.
- Key operational functions initially supplied via a transition services arrangement, including customer support and product support, have all successfully transitioned to Alcidion.
- Discussions with select customers about expanding their use of the broader Miya platform are progressing well.

Miya Patient Administration Launch

Miya Patient Administration targets a significant replacement opportunity created by ageing patient administration systems (PAS) across healthcare and is designed to change how administrative teams work and accelerate access to care. It takes advantage of the Miya platform’s intuitive user interface, real-time integration capabilities and strong foundation for AI. Built from the ground up on the Miya platform, it draws on the deep PAS experience and customer engagement gained through PCS.

Miya Patient Administration is designed to shorten the time from referral to booking, keep waiting lists validated and prioritised as they change, give earlier sight of bed and theatre capacity and reduce duplicate data entry. Leveraging FHIR standards, Miya Patient Administration integrates in real time with other hospital systems and will enable hospitals to natively start with the patient administration modules and add other Miya solutions over time or add it to an existing Miya deployment.

Miya Patient Administration is applicable across all Alcidion’s current geographies and, based on engagement with both current and prospective customers, the Company sees a significant market opportunity.

Capital Management

As Alcidion continues to strengthen its financial profile, improve profitability and generate cash, the Board has greater flexibility to implement strategies that drive shareholder value in line with a defined capital allocation framework. The framework balances investment in the Miya platform (such as Miya Patient Administration), expansion into new markets, potential strategic acquisitions and capital returns.

The recently announced on-market share buy-back and share consolidation form part of this framework.

On-market Share Buy-back

As announced on 27 October 2026, Alcidion will undertake an on-market share buy-back program (**Buy-back**) for up to 10% of the Company's issued capital, equating to approximately 135 million ordinary shares (approximately 13.5 million shares following the Consolidation, if approved).

The Buy-back is expected to commence on or around 10 November 2026 and continue for up to 12 months, unless completed or terminated earlier. The 10% limit represents the maximum number of shares that may be acquired, rather than a target or commitment to purchase that amount.

The Board intends to use the Buy-back selectively, where purchases are expected to deliver compelling value for shareholders and sufficient cash reserves remain to support operating requirements and growth priorities. Buy-back decisions will be assessed alongside other potential uses of capital, considering their relative expected returns and the importance of maintaining financial flexibility.

The timing, number and value of shares purchased will depend on the prevailing share price, business and market conditions, available cash reserves, other investment opportunities and the Board's assessment of the expected benefits to shareholders. Purchases may therefore be intermittent, and the Company may suspend or terminate the program as circumstances and capital allocation priorities evolve.

Share Consolidation

As announced on 9 October 2026, Alcidion intends to undertake a consolidation of its issued capital, whereby, subject to shareholder approval, every 10 shares will be consolidated into 1 share (Consolidation).

The Consolidation is intended to simplify Alcidion's capital structure by aligning the number of shares on issue with the Company's growing scale and making Alcidion more readily comparable with relevant listed peers. It is also expected to support more efficient trading, as a higher share price reduces the minimum ASX price increment as a percentage of the share price.

The Consolidation will not alter the underlying value of shareholders' shareholdings or their proportional ownership in the Company, other than minor changes resulting from the treatment of fractional entitlements.

Outlook

As of 30 September 2026, Alcidion has FY27 contracted (sold and renewal) revenue of \$50.0M, up 38% on pcip, with new sales expected to increase this figure over the remaining 8 months of FY27.

Alcidion reconfirms its FY27 financial guidance for revenue and Underlying EBITDA to exceed FY26.

The Company continues to deliver on its land-and-expand strategy across all core geographies and, with growing customer referenceability, is confident of securing further new customers and module expansions over the remainder of the year. Demand for modern electronic patient records, patient flow and virtual care solutions continues to grow as health systems prioritise reducing wait times and making the best use of bed capacity.

ENDS

Authorised for ASX release by the Board of Directors of Alcidion Group Limited

For further information, please contact:

Investor Relations

investor@alcidion.com

About Alcidion

Alcidion Group Limited (Alcidion) has a simple purpose: to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver clinical decision support at the point of care; all in support of Alcidion's mission to improve patient outcomes.

Since listing on the ASX in 2016, Alcidion has acquired multiple healthcare IT companies and now operates across three established markets — Australia, New Zealand and the United Kingdom — serving hospitals and healthcare organisations at scale, with further geographical expansion planned.

With over 25 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

www.alcidion.com

© Alcidion Group Limited 2026